Highly active anti-Pneumocystis carinii compounds in a library of novel piperazine-linked bisbenzamidines and related compounds

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 11, 2004, Pages 4209-4216

  Cushion, Melanie T ^a,b   Walzer, Peter D ^a,b   Collins, Margaret S ^a,b   Rebholz, Sandra ^a,b   Vanden Eynde, Jean Jacques ^c   Mayence, Annie ^c   Huang, Tien L ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' (1,4 PIPERAZINEDIYL)BIS(N CYCLOBUTYL BENZENECARBOXIMIDAMIDE); 4,4' (1,4 PIPERAZINEDIYL)BIS(N CYCLOHEPTYL BENZENECARBOXIMIDAMIDE); 4,4' (1,4 PIPERAZINEDIYL)BIS(N CYCLOOCTYL BENZECARBOXIMIDAMIDE; 4,4' (1,4 PIPERAZINEDIYL)BIS(N DECYL BENZENECARBOXIMIDAMIDE); 4,4' (1,4 PIPERAZINEDIYL)BIS(N DODECYL BENZENECARBOXIMIDAMIDE); 4,4' (1,4 PIPERAZINEDIYL)BIS(N ETHYL BENZENECARBOXIMIDAMIDE); 4,4' (1,4 PIPERAZINEDIYL)BIS(N HEPTYL BENZENECARBOXIMIDAMIDE); 4,4' (1,4 PIPERAZINEDIYL)BIS(N HEXYL BENZENECARBOXIMIDAMIDE); 4,4' (1,4 PIPERAZINEDIYL)BIS(N NONYL BENEZENECARBOXIMIDAMIDE); 4,4' (1,4 PIPERAZINEDIYL)BIS(N OCTYL BENZENECARBOXIMIDAMIDE); 4,4' (1,4 PIPERAZINEDIYL)BIS[N (2 METHYLBUT 1 YL)BENZENECARBOXIMIDAMIDE]; 4,4' (1,4 PIPERAZINEDIYL)BIS[N (4 METHYLBUT 1 YL)BENZENECARBOXIMIDAMIDE]; 4,4' (1,4 PIPERAZINEDIYL)BIS[N PENTYL BENZENECARBOXIMIDAMIDE]; ADENOSINE TRIPHOSPHATE; ANTIPROTOZOAL AGENT; BISBENZAMIDINE DERIVATIVE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MAMMAL CELL; PNEUMOCYSTIS; PNEUMOCYSTIS CARINII; PNEUMONIA; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TOXICITY TESTING;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIFUNGAL AGENTS; BENZAMIDINES; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; HUMANS; INDICATORS AND REAGENTS; LUCIFERASES; MICROBIAL SENSITIVITY TESTS; PIPERAZINES; PNEUMOCYSTIS CARINII; RATS; RATS, INBRED BN; RATS, LONG-EVANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 7244238109     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.11.4209-4216.2004     Document Type: Article

References (42)

1. Armstrong, W., S. Meshnick, and P. Kazanjian. 2000. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in immunocompromised patients. Microbes Infect. 2:61-67.
2. Assan, R., C. Perronne, D. Assan, L. Chotard, C. Mayaud, S. Matheron, and D. Zucman. 1995. Pentamidine-induced derangements of glucose homeostasis: determinant roles of renal failure and drug accumulation. A study of 128 patients. Diabetes Care 18:47-55.
3. Bell, C. A., C. C. Dykstra, N. A. Naiman, M. Cory, T. A. Fairley, and R. R. Tidwell. 1993. Structure-activity studies of dicationically substituted bis-benzamidazoles against Giardia lamblia: correlation of antigiardial activity with DNA-binding affinity and giardial topoisomerase II inhibition. Antimicrob. Agents Chemother. 37:2668-2773.
4. Berg, S. S. 1960. Search for chemotherapeutic amidines-(XVII)- alpha, omega-bis (p-amidinoanilino) alkanes. J. Chem. Soc. 5172-5176.
5. Bray, P. G., M. P. Barrett, S. A. Ward, and H. P. de Koning. 2003. Pentamidine uptake and resistance in pathogenic protozoa: past, present, and future. Trends Parasitol. 19:232-239.
6. Chen, F., and M. T. Cushion. 1994. Use of an ATP bioluminescent assay to evaluate viability of Pneumocystis carinii from rats. J. Clin. Microbiol. 32:2791-2800.
7. Collins, M. S., and M. T. Cushion. 2001. Standardization of an in vitro drug screening assay by use of cryopreserved and characterized Pneumocystis carinii populations. J. Eukaryot. Microbiol. 2001(Suppl.):178S-179S.
8. Cushion, M. T., F. Chen, and N. Kloepfer. 1997. A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents. Antimicrob. Agents Chemother. 41:379-384.
9. Cushion, M. T., M. Kaselis, S. L. Stringer, and J. R. Stringer. 1993. Genetic stability and diversity of Pneumocystis carinii infecting rat colonies. Infect. Immun. 61:4801-4813.
10. Cushion, M. T., S. Orr, S. P. Keely, and J. R. Stringer. 2001. Time between inoculations and karyotype forms of Pneumocystis carinii f.sp. carinii influence outcome of experimental coinfections in rats. Infect. Immun. 69:97-107.
11. Cushion, M. T., and P. D. Walzer. 2004. In vitro and in vivo testing of new compounds. In P. D. Walzer and M. T. Cushion (ed.), Pneumocystis pneumonia, in press. Marcel-Dekker, Inc., New York, N.Y.
12. Donkor, I. O., T. L. Huang, B. Tao, D. Rattendi, S. Lane, M. Vargas, B. Goldenberg, and C. J. Bacchi. 2003. Trypanocidal activity of conformationally restricted pentamidine congeners. J. Med. Chem. 46:1041-1048.
13. Dykstra, C. C., and R. R. Tidwell. 1991. Inhibition of topoisomerases from Pneumocystis carinii by aromatic dicationic molecules. J. Protozool. 38:78S-81S.
14. Fishman, J. A. 1998. Treatment of infection due to Pneumocystis carinii. Antimicrob. Agents Chemother. 42:1309-1314.
15. Hall, J. E., J. E. Kerrigan, K. Ramachandran, B. C. Bender, J. P. Stanko, S. K. Jones, D. A. Patrick, and R. R. Tidwell. 1998. Anti-Pneumocystis activities of aromatic diamidoxime prodrugs. Antimicrob. Agents Chemother. 42:666-674.
16. Hughes, W. T., P. C. McNabb, T. D. Makres, and S. Feldman. 1974. Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis. Antimicrob. Agents Chemother. 5:289-293.
17. Ioannidis, J. P., D. O. Dixon, M. McIntosh, J. M. Albert, S. A. Bozzette, and S. M. Schnittman. 1999. Relationship between event rates and treatment effects in clinical site differences within multicenter trials: an example from primary Pneumocystis carinii prophylaxis. Control Clin. Trials 20:253-266.
18. Ivady, G., and L. Paldy. 1958. Ein neves Behandlungsverfahren der interstitiellen plasmazelligen Pneumonie Fruhgeborener mit funfwertigen Stibium und aromatischen Diamidinen. Monatsschr. Kinderheilkd. 106:10-15.
19. Ivady, G., L. Paldy, M. Koltay, G. Toth, and Z. Kovacs. 1967. Pneumocystis carinii pneumonia. Lancet 1:616-617.
20. Kaneshiro, E. S., M. S. Collins, and M. T. Cushion. 2000. Inhibitors of sterol biosynthesis and amphotericin B reduce the viability of Pneumocystis carinii f.sp. carinii. Antimicrob. Agents Chemother. 44:1630-1638.
21. Kazanjian, P., W. Armstrong, P. A. Hossler, W. Burman, J. Richardson, C. H. Lee, L. Crane, J. Katz, and S. R. Meshnick. 2000. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J. Infect. Dis. 182:551-557.
22. Liu, Y., R. R. Tidwell, and M. J. Leibowitz. 1994. Inhibition of in vitro splicing of a group I intron of Pneumocystis carinii. J. Eukaryot. Microbiol. 41:31-38.
23. Mayence, A., J. J. Vanden Eynde, and T. L. Huang. 2004. Evidences for the formation of bisbenzamidine-heme complexes in cell-free systems. Bioorg. Med. Chem. Lett. 14:1625-1628.
24. Mayence, A., J. J. Vanden Eynde, F. M. Krogstad, D. J. Krogstad, M. T. Cushion, and T. L. Huang. 2004. Parallel solution-phase synthesis of conformationally restricted congeners of pentamidine and evaluation of their antiplasmodial activities. J. Med. Chem. 47:2700-2705.
25. Mayence, A., J. J. Vanden Eynde, L. LeCour, Jr., L. A. Walker, B. L. Tekwani, and T. L. Huang. 2004. Piperazine-linked bisbenzamidines: a novel class of antileishmanial agents. Eur. J. Med. Chem. 39:547-553.
26. Mei, Q., S. Gurunathan, H. Masur, and J. A. Kovacs. 1998. Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene. Lancet 351:1631-1632.
27. Meshnick, S. R. 1999. Drug-resistant Pneumocystis carinii. Lancet 354:1318-1319.
28. Queener, S. F. 1995. New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii. J. Med. Chem. 38:4739-4759.
29. Roger, R., and D. G. Neilson. 1961. The chemistry of imidates. Chem. Rev. 61:179-211.
30. Suzuki, T., H. Ono, and M. Yokoyama. 1986. Bishydrazone compounds. Chem. Abstr. 105:15213g.
31. Tao, B., T. L. Huang, Q. Zhang, L. Jackson, S. F. Queener, and I. O. Donkor. 1999. Synthesis and anti-Pneumocystis carinii activity of conformationally restricted analogues of pentamidine. Eur. J. Med. Chem. 34:531-538.
32. Thampi, N. S., F. W. Schueler, and V. B. Vernon. 1967. Photosensitizing activity of N,N′-bis (p-formylphenyl) piperazine. J. Med. Chem. 10:111-112.
33. Tidwell, R. R., J. D. Geratz, W. A. Clyde, Jr., K. U. Rosenthal, and E. J. Dubovi. 1984, Suppression of respiratory syncytial virus infection in cotton rats by bis(5-amido-2-benzimidiazolyl)methane. Antimicrob. Agents Chemother. 26:591-593.
34. Vanden Eynde, J. J., A. Mayence, L. LeCour, Jr., and T. L. Huang. 2004. Synthesis, antituberculosis activity, and DNA binding affinity of a highly diverse library of 1,4-diarylpiperazines. Med. Chem. Res. 12:401-414.
35. van Dross, R. T., and M. M. Sanders. 2002. Molecular characterization of recombinant Pneumocystis carinii topoisomerase I: differential interactions with human topoisornerase I poisons and pentamidine. Antimicrob. Agents Chemother. 46:2145-2154.
36. 2+, pentamidine, and WR-6026 on mitochondrial membrane potential in situ. Biochem. J. 284:463-467.
37. Walker, D. J., A. E. Wakefield, M. N. Dohn, R. F. Miller, R. P. Baughman, P. A. Hossler, M. S. Bartlett, J. W. Smith, P. Kazanjian, and S. R. Meshnick. 1998. Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure. J. Infect. Dis. 178:1767-1775.
38. Walzer, P. D. 2000. Pneumocystis carinii, p. 2781-2795. In G. L. Mandell, J. E. Bennet, and P. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, Inc., New York, N.Y.
39. Walzer, P. D., A. Ashbaugh, M. Collins, and M. T. Cushion. 2001. In vitro and in vivo effects of quinupristin-dalfopristin against Pneumocystis carinii. Antimicrob. Agents Chemother. 45:3234-3237.
40. Winkelman, E., W. Raether, W. Dittmar, D. Duewel, D. Gericke, W. Hohorst, H. Rolly, and E. Schrinner. 1975. Chemotherapeutically active nitro compounds. 1. Nitroanilines. Arzneim-Forsch. 25:681-708.
41. Zhang, Y., Z. Li, D. S. Pilch, and M. J. Leibowitz. 2002. Pentamidine inhibits catalytic activity group I intron Ca.LSU by altering RNA folding. Nucleic Acids Res. 30:2961-2971.
42. Zingale, A., P. Carrera, A. Lazzarin, and P. Scarpellini. 2003. Detection of Pneumocystis carinii and characterization of mutations associated with sulfa resistance in bronchoalveolar lavage samples from human immunodeficiency virus-infected subjects. J. Clin. Microbiol. 41:2709-2712.